29th week of 2011 patent applcation highlights part 34 |
Patent application number | Title | Published |
20110177035 | USE OF SECRETOR, LEWIS AND SIALYL ANTIGEN LEVELS IN CLINICAL SAMPLES AS PREDICTORS OF RISK FOR DISEASE - An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis | 2011-07-21 |
20110177036 | WHOLE BLOOD CULTURES COMPRISING STIMULATED IMMUNE CELLS, AND USE THEREOF AS MEDICAMENTS - The present invention relates to a whole-blood culture containing specific immunocompetent killer cells that are activated against tumor cells, viruses, bacteria and/or allergens, whereby the whole-blood culture consists of whole-blood and a culture medium at a ratio of 3:1 to 4:1, whereby the culture medium has an oxygen excess of at least 100% or more and contains a water-soluble emulsification product comprising a mixture of phospholipids, vitamin E, and low-molecular proteoglycans with a molecular weight of 1,200 to 12,000 Dalton, and whereby dead tumor cells or fragments thereof and/or viral and/or bacterial antigens and/or allergens have been added to the whole-blood culture [to serve] as antigen in the specific recognition process for production of the activated killer cells (stimulation). The invention also relates to a method for producing the culture, as well as stimulants for the whole-blood culture and a method for the selection thereof. | 2011-07-21 |
20110177037 | Solenopsis invicta Virus | 2011-07-21 |
20110177038 | Inhibition of Tumor Growth via Peroxiredoxin 3 - Deregulated expression of the c-Myc transcription factor is found in a wide variety of human tumors. Because of this significant role in oncogenesis, considerable effort has been devoted to elucidating the molecular program initiated by deregulated c-myc expression. The primary transforming activity of Myc is thought to arise through transcriptional regulation of numerous target genes. Thus far, Myc target genes involved in mitochondrial function have not been characterized in depth. Here, we describe a nuclear c-Myc target gene, PRDX3, which encodes a mitochondrial protein of the peroxiredoxin gene family. Expression of PRDX3 is induced by the mycER system and is reduced in c-myc−/− cells. Chromatin immunoprecipitation analysis spanning the entire PRDX3 genomic sequence reveals that Myc binds preferentially to a 930-bp region surrounding exon 1. We show that PRDX3 is required for Myc-mediated proliferation, transformation, and apoptosis after glucose withdrawal. Results using mitochondria-specific fluorescent probes demonstrate that PRDX3 is essential for maintaining mitochondrial mass and membrane potential in transformed rat and human cells. These data provide evidence that PRDX3 is a c-Myc target gene that is required to maintain normal mitochondrial function. | 2011-07-21 |
20110177039 | ADULT BONE MARROW CELL TRANSPLANTATION TO TESTES CREATION OF TRANSDIFFERENTIATED TESTES GERM CELLS, LEYDIG CELLS AND SERTOLI CELLS - This invention pertains to the discovery that stem cells (e.g., bone marrow stem cells) transplanted directly into a testicular environment are transdifferentiated into bona fide Sertoli cells, and/or Leydig cells, and/or and germ cells. This provides a mechanism for the treatment of male infertility and/or testosterone deficiency. Thus, in one embodiment, this invention provides a method of treating infertility or testosterone deficiency in a male mammal. The method typically involves implanting stem cells into the testes of the mammal whereby the stem cells differentiate into germ cells and/or Sertoli cells and/or Leydig cells thereby reducing infertility and/or testosterone deficiency. | 2011-07-21 |
20110177040 | Cytokine Induction Of Selectin Ligands On Cells - Methods and compositions for treating cells with cytokines are provided herein. | 2011-07-21 |
20110177041 | MATERIAL FOR TREATMENT OF CEREBRAL INFARCTION AND BRAIN TISSUE REGENERATION METHOD - Disclosed is a therapeutic material for cerebral infarction, which can recover a vascular disorder in an area affected by cerebral infarction to improve the brain function. The therapeutic material for cerebral infarction includes a dental pulp stem cell comprising at least one member selected from a CD105-positive cell, an SP cell, a CD24-positive cell, a CD133-positive cell, a CD271-positive cell and a CD150-positive cell. The therapeutic material may additionally include a protein secreted from a dental pulp cell. A transplanted dental pulp stem cell cannot be differentiated directly into a neural progenitor cell or a neurocyte, but is involved indirectly in the promotion of differentiation to eliminate an area affected by cerebral infarction, thereby recovering the affected area into a normal area. | 2011-07-21 |
20110177042 | Method for Dedifferentiating Melanocytes - The present invention features a method for producing a dedifferentiated melanocyte. The method involves contacting a melanocyte with an agent that activates Notch1 and selecting for a dedifferentiated melanocyte which exhibits a premelanoma stem cell-like state. Agents for activating Notch1 and methods for using the cells and agents are also provided. | 2011-07-21 |
20110177043 | METHOD OF IMPROVING DIFFERENTIATION OF CHONDROGENIC PROGENITOR CELLS - We disclose a method of promoting cartilage, bone or ligament repair or inducing repair or regeneration of chondral tissue, the method comprising enhancing the expression or activity of ZNF145 or a fragment, homologue, variant or derivative thereof in an chondrogenic progenitor cell, for example a mesenchymal stem cell. We also provide for a chondrogenic progenitor cell, for example a mesenchymal stem cell (MSC) engineered to increase expression or activity of ZNF145 or a fragment, homologue, variant or derivative thereof. | 2011-07-21 |
20110177044 | Nutritional Formulas Containing Synbiotics - The present disclosure relates to a synbiotic composition comprising the probiotic | 2011-07-21 |
20110177045 | Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 2011-07-21 |
20110177046 | DITHIAZOLIDINE AND THIAZOLIDINE DERIVATIVES AS ANTICANCER AGENTS - There is provided a compound of formula (I): wherein Y has the meaning given in the description. Such compounds are potentially useful in the treatment of disorders or conditions caused by, linked to, or contributed to by, excess adiposity, such as hyperinsulinemia and type 2 diabetes. | 2011-07-21 |
20110177047 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2011-07-21 |
20110177048 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms. | 2011-07-21 |
20110177049 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 2011-07-21 |
20110177050 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 2011-07-21 |
20110177051 | METHODS AND COMPOSITIONS FOR TREATMENT OF MITOCHONDRIAL DISORDERS - The present invention concerns in general novel fusion proteins comprising a membrane-transferring moiety and an enzymatic moiety. The present invention further concerns a method of treating disease using said fusion proteins. | 2011-07-21 |
20110177052 | Stabilized Proteases For Use In Skin Care - Disclosed is an invention which relates to synthesizing immobilized and crosslinked proteases derived from plants for use as skin care agents. The resulting stabilized protease will minimally penetrate the skin because of its immobilized nature. It will retain activity because of its crosslinked nature and, in certain embodiments, due to its stabilization via physical additives. The present invention relates in particular to a linked papain product used in topical skin applications. | 2011-07-21 |
20110177053 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 2011-07-21 |
20110177054 | USE OF ENDO-LYSOSOMAL SYSTEM AND SECRETED VESICLES (EXOSOME-LIKE) IN TREATMENTS AND DIAGNOSTICS BASED ON SMALL RNA AND EXPERIMENTAL STUDY OF SMALL RNA - The present invention relates to a method for determining the delivery rates and/or efficiency of a siRNA, miRNA or related molecule to target organs or cells, a kit and the use of proteins or lipids involved in the formation of the endolysosomal system for modulating the activity and/or the cell-to-cell transfer of RNA, small RNA, for example miRNA, siRNA and piRNA, mRNA or non-coding RNA. | 2011-07-21 |
20110177055 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase, | 2011-07-21 |
20110177056 | NON-CYTOTOXIC FUSION PROTEINS COMPRISING EGF MUTEINS - The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumours, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer. | 2011-07-21 |
20110177057 | PHARMACEUTICAL PREPARATION AND MANUFACTURING METHOD THEREOF - This invention provides a pharmaceutical preparation for DDS containing a pharmaceutical agent fixed by bonding to a monomolecular layer that is covalently bonded to a magnetic particle surface, (a) by reacting an alkoxysilane compound with the magnetic microparticle surface by dispersing a magnetic microparticle in a liquid mixture including an epoxy-containing alkoxysilane compound, a silanol condensation catalyst, and a non-aqueous organic solvent; (b) by washing the microparticle surface with an organic solvent to remove remaining surplus alkoxysilane compound for producing an epoxy-containing monomolecular layer that is covalently bonded to the microparticle surface; and (c) by fixing an imino-containing pharmaceutical agent such as a protein, amino acid, enzyme, antibody, antibiotic, antimicrobial, or contrast medium by reaction with the epoxy group. | 2011-07-21 |
20110177058 | METHODS AND COMPOSITIONS FOR MODULATING HGF/MET - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met. | 2011-07-21 |
20110177059 | PSA AND KLK2 AS THERAPEUTIC TARGETS AND MOLECULES INHIBITING PSA AND KLK2 - Disclosed herein are compositions and methods relating to prostate-specific antigen (PSA), KLK2 and androgen receptor. Further provided are methods and compositions for inhibiting PSA and/or KLK2 activity. Further provided are compositions and methods for treating or preventing cancer. | 2011-07-21 |
20110177060 | IAP BIR DOMAIN BINDING COMPOUNDS - IAP BIR domain binding compounds of Formula (I), (II), (III), or (IV), and the use thereof, for example, for the treatment or prevention of proliferative diseases. | 2011-07-21 |
20110177061 | METHODS OF TREATING AND PREVENTING NEUROLOGICAL DISORDERS USING DOCOSAHEXAENOIC ACID - The disclosure relates to methods of treating or preventing neurological disorders using docosahexaenoic acid. | 2011-07-21 |
20110177062 | METHODS FOR TREATING BREAST CANCER - The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies. | 2011-07-21 |
20110177063 | METHODS FOR TREATING COLORECTAL CANCER - The present disclosure is directed to methods of treating and preventing colorectal cancer metastasis or recurrence of colorectal cancer with compositions comprising anti-progastrin antibodies. | 2011-07-21 |
20110177064 | Compositions and Methods for Treatment of Ovarian Cancer - The present invention relates to surprisingly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g.,, an immunoconjugate) in combination with at least two chemotherapeutic agents (in particular a taxane compound and a platinum compound), improves the therapeutic index in the treatment of ovarian cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus additional chemotherapeutic agents have a synergistic effect in the ovarian cancer therapeutic index. The present invention also provides methods of modulating the growth of selected cell populations, such as ovarian cancer cells, by administering a therapeutically effective amount of such combinations. | 2011-07-21 |
20110177065 | METHODS OF TREATING/PREVENTING INFLAMMATION USING COMBINATION OF IL-1 ANTAGONIST AND IL-18 BINDING PROTEIN - The invention relates to the combined use of an IL-1 antagonist/inhibitor and IL-18 binding protein in inflammatory diseases. | 2011-07-21 |
20110177066 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Passive immunotherapy methods for treating a patient having AL amyloidosis characterized by the presence of amyloid light chain-type protein fibrils. | 2011-07-21 |
20110177067 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine. | 2011-07-21 |
20110177068 | PHARMACEUTICAL PREPARATION COMPRISING AN ANTIBODY AGAINST THE EGF RECEPTOR - The invention relates to an aqueous pharmaceutical preparation comprising an antibody against endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and can be used for the treatment of tumours. | 2011-07-21 |
20110177069 | NOVEL INDUCER OF CHONDROCYTE PROLIFERATION AND DIFFERENTIATION - This invention provides a method for administration of an effective amount of RANKL-binding molecules that act on prechondrocytes and/or mesenchymal stem cells, accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation to induce chondrocyte proliferation and differentiation or increase cartilage matrix production and a pharmaceutical composition used for inducing chondrocyte proliferation and differentiation or increasing cartilage matrix production. The pharmaceutical composition used for treatment or prevention of a chondropathies comprises, as an active ingredient, a compound that acts on prechondrocytes and/or mesenchymal stem cells and induces at least one of the following: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix. | 2011-07-21 |
20110177070 | TGF-Beta Antagonist Multi-Target Binding Proteins - This disclosure provides a multi-target fusion protein composed of a TGF? antagonist domain and another binding domain antagonistic for a heterologous target (such as IL6, IL10, VEGF, TNF, HGF, TWEAK, IGF) or agonistic for a heterologous target (such as GITR). The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions. | 2011-07-21 |
20110177071 | IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided. | 2011-07-21 |
20110177072 | METHODS OF TREATING INFLAMMATION IN NEURONAL TISSUE - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2011-07-21 |
20110177073 | Recombinant production of mixtures of antibodies - Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields. | 2011-07-21 |
20110177074 | COMPOSITIONS AND METHODS FOR INHIBITING PDGFRBETA AND VEGF-A - Disclosed are antagonists of PDGF receptor β (PDGFRβ) and VEGF-A, including neutralizing anti-PDGFRβ and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRβ and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRβ and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRβ and/or VEGF-A antagonist. | 2011-07-21 |
20110177075 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-07-21 |
20110177076 | HUMANIZED ANTI-AMYLOID BETA ANTIBODIES - Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody. | 2011-07-21 |
20110177077 | PAX 5 MONOCLONAL ANTIBODY - The present invention relates to novel anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. In particular the invention relates to an antibody, antigen binding fragment or recombinant protein thereof, which is capable of specific binding to an epitope located within the C-terminal fragment of human PAX 5 protein, wherein said epitope comprises from 3 to 17 amino acid residues of amino acid sequence GSPYYYSAAARGAAPPA (SEQ ID NO:2). The invention also relates to immunogenic peptide sequences for the production of the antibodies, diagnostic and therapeutic applications comprising using the antibodies and formulations comprising thereof. | 2011-07-21 |
20110177078 | Immunogen and Antivenom Against Violin Spider Venom - The invention relates to the isolation, characterisation and expression of DNA fragments encoding sphingomyelinases D from three species of | 2011-07-21 |
20110177079 | Cancer-testis antigens - The invention relates to cancer-testis antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of novel cancer-testis (CT) antigens. | 2011-07-21 |
20110177080 | NOVEL P2X7 EPITOPES - The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer. | 2011-07-21 |
20110177081 | PHARMACEUTICAL COMPOSITIONS OF ANTIBODIES FOR DISEASES CAUSED BY VIRUSES - A pharmaceutical composition for prevention or treatment of viral infections including a formulation of full antibodies or fragments of antibodies specific to at least one of the following peptide sequences of toll-like receptor type 3: FYWNVSVHRVLGFKE (Seq ID NO:1), EYAAYIIHAYKD (Seq ID NO: 2), or to peptide sequence of interferon gamma receptor beta chain: LIKYWFHTPPSIPLQIEEYL (Seq ID NO: 3), or to peptide sequence of interferon gamma receptor alpha chain: SIILPKSLISW (Seq ID NO: 4). | 2011-07-21 |
20110177082 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAN CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer. | 2011-07-21 |
20110177083 | SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners. | 2011-07-21 |
20110177084 | NOVEL USE APPLICATION OF SUGAR CHAIN-RECOGNIZING RECEPTOR - Provided are a novel means for regulating inflammatory reactions by regulating the signaling in inflammatory responses caused by non-homeostatic cell death, specifically an anti-inflammatory agent comprising a substance that inhibits the expression of Mincle or the interaction of Mincle and SAP130 or FcRγ, a screening method for a substance that regulates inflammatory reactions, comprising contacting Mincle or a fragment containing an extracellular region thereof and SAP130 in the presence and absence of a test substance, and comparing the degrees of the interaction of Mincle or the fragment thereof and SAP130 under the two conditions, a method of detecting non-homeostatic cell death, comprising measuring the amount of SAP130 in a sample collected from a subject animal, and the like. | 2011-07-21 |
20110177085 | Bitter Taste Receptors - The present invention relates to bitter-taste receptors and their role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block, bitter taste transduction, or enhance bitter taste response. | 2011-07-21 |
20110177086 | METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated. | 2011-07-21 |
20110177087 | HUMAN ANTI-PSEUDOMONAS-AERUGINOSA ANTIBODIES DERIVED FROM TRANSGENIC XENOMOUSE - The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein. | 2011-07-21 |
20110177088 | Method for Treating and Diagnosing Hematologic Malignancies - The invention relates to methods for treating and diagnosing hematologic malignancies, Chronic lymphocytic leukemia and Small Lymphocytic Lymphoma in particular, using PD-1 ligands (PD-L1, PD-L2 or anti-PD-1 antibodies). | 2011-07-21 |
20110177089 | APOPTOSIS INDUCER - Provided is an agent which is useful for diagnosis, prevention, and treatment of various diseases induced by an oxidative stress. Disclosed are secreted eIF5A protein and a pharmaceutical containing the same. | 2011-07-21 |
20110177090 | Glycan markers and autoantibody signatures in HIV-1 and HIV-1-associated malignancies - The present invention provides compositions and methods for the specific and sensitive detection and characterization of anti-carbohydrate antibodies against immunogenic sugar moieties on microbes and abnormal cells and anti-HIV-1 protein antibodies for the development of diagnostic, prophylactic and therapeutic strategies against diseases inflicted by cancer cells or microbial pathogens. | 2011-07-21 |
20110177091 | Inhibition of Tumor Angiogenesis by Inhibition of Peroxiredoxin 1 (PRX1) - Provided is a method for inhibiting angiogenesis in a tumor. The method involves administering to an individual who has a tumor a composition that contains an agent capable of inhibiting binding of peroxiredoxin 1 (Prx1) to Toll like receptor 4 (TLR4) such that angiogenesis in the tumor is inhibited subsequent to the administration. The agent that is capable of inhibiting binding of Prx1 to TLR4 can be an antibody to Prx1, a Prx1 binding fragment of the antibody, or a peptide. The peptide can be capable of inhibiting the formation of a Prx1 decamer, or can inhibit binding of Prx1 to TLR4 by steric interference, or by competitions with Prx1 for TLR4 binding. The tumor in which angiognesis is inhibited can be any type of cancer tumor. | 2011-07-21 |
20110177092 | INDIVIDUAL 5-FLUOROURACILE DOSE OPTIMIZATION IN FOLFIRI TREATMENT - The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention. | 2011-07-21 |
20110177093 | USE OF BCMA AS AN IMMUNOREGULATORY AGENT - The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF. | 2011-07-21 |
20110177094 | IVIG MODULATION OF CHEMOKINES FOR TREATMENT OF MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, AND PARKINSON'S DISEASE - The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease. | 2011-07-21 |
20110177095 | ANTI-HER2 ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2. | 2011-07-21 |
20110177096 | USE OF GPR151 MODULATORS FOR THE TREATMENT OF PAIN - The present invention relates to nucleic acid arrays used to detect genes which are up or down regulated following a pain stimulus in a mammal. It further relates to the use of GPR151 in methods to detect pain or evaluate the effect of a compound on the level of pain in a mammal. Other aspects of the invention concern a method for screening pharmaceuticals, methods for the treatment of pain and a pharmaceutical composition comprising a GPR151 modulator for the treatment of pain. | 2011-07-21 |
20110177097 | METHODS FOR MODULATING EXPRESSION OF CREB - Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of CREB. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a CREB-specific inhibitor. | 2011-07-21 |
20110177098 | TM4SF4 AND MODULATORS THEREOF AND METHODS FOR THEIR USE - The present invention relates to methods for modulating a β-cell population using a TM4SF4 modulator or a modulator of a TM4SF4 homolog. More particularly, the invention relates, inter alia, to methods and compositions for generating, expanding, and maintaining a β-cell population and treatment of diseases associated with the loss of β-cells using a TM4SF4 modulator or a modulator of a TM4SF4 homolog. | 2011-07-21 |
20110177099 | GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE - Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer. | 2011-07-21 |
20110177100 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-07-21 |
20110177101 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-07-21 |
20110177102 | TARGETED DOUBLE STRANDED RNA MEDIATED CELL KILLING - A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter which comprises a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue. | 2011-07-21 |
20110177103 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2011-07-21 |
20110177104 | METHOD FOR SELECTIVE DEPLETION OF CD137 POSITIVE CELLS USING ANTI-CD137 ANTIBODY-TOXIN COMPLEX - The present invention relates to method for depletion of CD137 positive cells using an anti-CD137 antibody-toxin complex, and more particularly, to a method for selective depletion of CD137 positive cells, comprising the step of contacting an anti-CD137 antibody-toxin complex with the CD137 positive cells. The method for selective depletion of CD137 positive cells in accordance with the present invention can be useful to prevent or treat various diseases including immune diseases mediated by the activation of the CD137 positive cells because this method is excellent in delivering a complex of an anti-CD137 antibody, specific to CD137 molecules, and a toxin to CD137 expressing cells and selectively killing the CD137 positive cells alone and is also excellent in suppressing cell proliferation. | 2011-07-21 |
20110177105 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications - The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use. | 2011-07-21 |
20110177106 | Novel Therapeutic Methods for Treating Inflammation and Immune System Disorders - The subject invention provides novel and advantageous materials and methods for treating neuroinflammation, neurodegenerative disease, and cerebrovascular disease by modulating TNF-α and/or nitric oxide production. Specifically exemplified herein is the therapeutic use of senkyunolide A (Sen A) and Z-ligustilide (Z-Lig), compounds isolated from traditional Chinese medicinal material | 2011-07-21 |
20110177107 | PREDICTING AND REDUCING ALLOIMMUNOGENICITY OF PROTEIN THERAPEUTICS - Methods of predicting the immunogenicity of a therapeutic protein in a subject are provided and the use of this method in selecting a protein for replacement therapy having the fewest immunogenic epitopes. The method is demonstrated by reference to ADAMTS13. Isolated allelic variants of ADAMTS13 that contribute to the variability in risk for both arterial and venous thrombotic disease development are provided. The allelic variants are identified as single nucleotide polymorphisms (ns-SNPs) in the ADAMTS13 gene, which result in haplotypes identified as H1 to H14. A method for improving outcomes of transfusions/transplant products is also provided by selection of haplotype matched therapeutics. | 2011-07-21 |
20110177108 | LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS - The present invention provides compounds, or pharmaceutically acceptable salts or analogs thereof, which exhibit anti-tumor activity. The present invention also includes methods for inhibiting the growth of cancer cells by contacting an effective amount of a compound of the present invention with the cancer cells in vitro or in vivo. | 2011-07-21 |
20110177109 | ANTIGENIC TAU PEPTIDES AND USES THEREOF - The present disclosure relates to novel immunogens and compositions comprising an antigenic tau peptide, preferably linked to an immunogenic carrier for use in the treatment of tau-related neurological disorders. The disclosure further relates to methods for production of these immunogens and compositions and their use in medicine. | 2011-07-21 |
20110177110 | COMPOSITIONS COMPRISING CATIONIC MICROPARTICLES AND HCV E1E2 DNA AND METHODS OF USE THEREOF - Immunogenic HCV E1E2 | 2011-07-21 |
20110177111 | PROTECTIVE VACCINE AGAINST STAPHYLOCOCCUS AUREUS BIOFILMS COMPRISING CELL WALL-ASSOCIATED IMMUNOGENS - Vaccine formulations effective against | 2011-07-21 |
20110177112 | MULTI- COMPONENT L2 VACCINE FOR PREVENTION OF HUMAN PAPILLOMA VIRUS INFECTION - Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope. | 2011-07-21 |
20110177113 | USE OF ANTRODIA CAMPHORATA FOR TREATING DISEASES - The present invention relates to the use of | 2011-07-21 |
20110177114 | IMMEDIATE PROTECTION AGAINST PATHOGENS VIA MVA - The invention relates to the methods and kits comprising modified vaccinia virus Ankara (MVA) to provide immediate protection against pathogens. MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen. | 2011-07-21 |
20110177115 | VACCINATION REGIMEN - The present invention provides a method of raising an immune response in a subject against an antigen. The method involves the steps of a) administering to the subject a non-atadenoviral vector comprising a nucleic acid encoding the antigen, and b) administering an engineered atadenovirus to the subject, wherein the genome of the engineered atadenovirus encodes the antigen. Step b) is performed after step a). | 2011-07-21 |
20110177116 | Methods of Immunizing Pregnant Heifers at Three Months of Gestation - The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle. | 2011-07-21 |
20110177117 | CHIMERIC RESPIRATORY SYNCYTIAL VIRUS POLYPEPTIDE ANTIGENS - Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first amino acid sequence comprising an F2 domain uncleavably joined to an F1 domain of a Respiratory Syncytial Virus (RSV) Fusion (F) protein polypeptide; and a second amino acid sequence comprising a portion of an RSV Attachment (G) protein polypeptide comprising an immunologically dominant epitope. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use. | 2011-07-21 |
20110177118 | Non-Simian Cells for Growth of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus - Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies. | 2011-07-21 |
20110177119 | STABLE, DRIED ROTAVIRUS VACCINE, COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF - The present invention provides novel lyophilized rotavirus vaccine formulations and methods of their preparation. The formulations include vaccine stabilizers, resulting in a vaccine formulation with enhanced stability and minimal loss of potency. The rotavirus vaccine formulations comprise an advantageous ratio of a disaccharide (such as sucrose) to an amino acid (such as glycine). The lyophilization results in a virus formulation with 100% virus preservation and residual moisture from about 0.8% to 1.4%. | 2011-07-21 |
20110177120 | MYCOBACTERIUM TUBERCULOSIS VACCINE - The present invention relates to the use of live mycobacterium of the | 2011-07-21 |
20110177121 | Immunogenic Influenza Composition - Novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host. | 2011-07-21 |
20110177122 | DNA PRIME/ACTIVATED VACCINE BOOST IMMUNIZATION TO INFLUENZA VIRUS - The present invention relates to a combination of a priming composition and a boosting composition to prime and boost an immune response in a subject whereby the immune response resulting from administration of the priming composition to the subject is capable of being boosted. The priming composition comprises a DNA plasmid that comprises a nucleic acid molecule encoding an influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof. The boosting composition comprises an influenza vaccine. The present invention also relates to a method to use such a combination to vaccinate a subject and to enhance an immune response to an influenza vaccine administered alone. Such a combination can elicit an immune response not only against at least one influenza virus strain from which the priming composition or boosting composition is derived but also to at least one heterologous influenza virus strain. | 2011-07-21 |
20110177123 | Recombinant Live Attenuated Foot-and-Mouth Disease (FMD) Vaccine Containing Mutations in the L Protein Coding Region - Previously we have identified a conserved domain (SAP, for SAF-A/B, Acinus, and PIAS) in the foot-and-mouth disease virus (FMDV) leader (L) protein coding region that is required for proper sub-cellular localization and function. Mutation of isoleucine 55 and leucine 58 to alanine (I55A, L58A) within the SAP domain resulted in a viable virus that displayed a mild attenuated phenotype in cell culture, along with altered sub-cellular distribution of L and failure to induce degradation of the transcription factor nuclear factor kappa-B. Here we report that inoculation of swine and cattle with this mutant virus results in the absence of clinical disease, the induction of a significant FMDV-specific neutralizing antibody response, and protection against subsequent homologous virus challenge. Remarkably, swine vaccinated with SAP mutant virus are protected against wild type virus challenge as early as two days post-vaccination suggesting that a strong innate as well as adaptive immunity is elicited. This variant could serve as the basis for construction of a live-attenuated FMD vaccine candidate. | 2011-07-21 |
20110177124 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators. | 2011-07-21 |
20110177125 | HSV-1 AND HSV-2 VACCINES AND METHODS OF USE THEREOF - This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other proteins. | 2011-07-21 |
20110177126 | BACTERIA AND DERIVED PRODUCTS TO REINFORCE THE BODY DEFENCES AND TO REDUCE THE RISK OF DISEASE - This invention relates to a new strain of the genus | 2011-07-21 |
20110177127 | Brucella Abortus Proteins and Methods of Use Thereof - Compositions and methods for the diagnosis and prevention of | 2011-07-21 |
20110177128 | IMMUNOTHERAPY COMPOSITIONS AND METHODS OF TREATMENT - Provided are compositions that include one or more natural, recombinant and/or modified allergens; with a pharmaceutically acceptable non-aqueous solvent to form an immunotherapy composition that includes the active ingredient and solvent, wherein the immunotherapy composition is formulated for administration to a subject in need of immunotherapy. The solvent is miscible with water and interstitial fluid. The at least one active ingredient is soluble in the solvent and insoluble in water and in an aqueous phase of interstitial fluid. The present compositions may be administered to a patient for example, as part of an immunotherapy regimen to help induce a state of immunologic tolerance to one or more allergies, or as treatment for an autoimmune disease. Also provided are methods of making such compositions. Further provided are methods that include administering the composition to a mammal. | 2011-07-21 |
20110177129 | Methods and Compositions Using Peroxiredoxin 1 (PRX1) as an Adjuvant - Provided are compositions and methods for stimulating immune responses against antigens. The compositions contain an antigen to which a stimulated immune response is desired and an isolated Prx1 protein. The Prx1 protein functions as an adjuvant so that the immune response to the antigen stimulated by the composition comprising the antigen and Prx1 is greater than the immune response stimulated by the antigen alone. | 2011-07-21 |
20110177130 | METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS - Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation. | 2011-07-21 |
20110177131 | siRNA SILENCING OF FILOVIRUS GENE EXPRESSION - The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid. | 2011-07-21 |
20110177132 | Compositions and Methods for Generating Musculoskeletal Tissue - The present disclosure provides compositions comprising musculoskeletal cells and mesenchymal stem cells in discrete regions. The present disclosure provides systems comprising a subject composition; and methods of using a subject composition to generate cartilage, bone, tendon, muscle, intervertebral disc, or other musculoskeletal tissues. | 2011-07-21 |
20110177134 | Viable Tissue Repair Implants and Methods of Use - Biocompatible tissue implants are provided for repairing a tissue injury or defect. The tissue implants comprise a biological tissue slice that serves as a source of viable cells capable of tissue regeneration and/or repair. The biological tissue slice can be harvested from healthy tissue to have a geometry that is suitable for implantation at the site of the injury or defect. The harvested tissue slice is dimensioned to allow the viable cells contained within the tissue slice to migrate out and proliferate and integrate with tissue surrounding the injury or defect site. Methods for repairing a tissue injury or defect using the tissue implants are also provided. | 2011-07-21 |
20110177135 | METHODS OF TREATING CARTILAGE DEFECTS - The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein. | 2011-07-21 |